| Acknowledgements |
|
viii | (1) |
| Preface |
|
ix | (2) |
| List of contributors |
|
xi | |
|
1 Definition and classification of osteorthritis |
|
|
1 | (12) |
|
|
|
|
|
|
|
|
|
|
|
2 Epidemiology of osteoarthritis |
|
|
13 | (10) |
|
|
|
|
|
|
3 The economics of osteoarthritis |
|
|
23 | (8) |
|
|
|
|
|
|
4 Hereditary osteoarthritis |
|
|
31 | (19) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5 Pathology of osteoarthritis |
|
|
50 | (12) |
|
|
|
|
|
|
6 Paleopathology of osteoarthritis |
|
|
62 | (8) |
|
|
|
|
|
|
7 Pathogenesis of osteoarthritis |
|
|
70 | (127) |
|
7.1 Introduction: the concept of osteoarthritis as failure of the diarthrodial joint |
|
|
70 | (4) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
74 | (70) |
|
7.2.1 Biochemistry and metabolism of normal and osteoarthritic cartilage |
|
|
74 | (10) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7.2.2 Proteolytic degradation of normal and osteoarthritic cartilage matrix |
|
|
84 | (10) |
|
|
|
|
|
|
|
|
|
|
|
7.2.3 Articular cartilage regeneration |
|
|
94 | (14) |
|
|
|
|
|
|
|
|
|
|
|
7.2.4 Mechanical properties of normal and osteoarthritic articular cartilage |
|
|
108 | (15) |
|
|
|
|
|
|
|
|
|
|
|
7.2.5 Response of the chondrocyte to mechanical stimuli |
|
|
123 | (14) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7.2.6 Crystals and osteoarthritis |
|
|
137 | (7) |
|
|
|
|
|
|
|
|
144 | (13) |
|
|
|
|
|
|
|
|
157 | (19) |
|
7.4.1 Synovial mediators of cartilage damage and repair in osteoarthritis |
|
|
157 | (10) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7.4.2 Synovial physiology in the context of osteoarthritis |
|
|
167 | (9) |
|
|
|
|
|
|
7.5 Innervation of the joint and its role in osteoarthritis |
|
|
176 | (12) |
|
|
|
|
|
|
7.6 Muscle in osteoarthritis |
|
|
188 | (9) |
|
|
|
|
|
|
|
|
|
|
|
8 Clinical features of osteoarthritis and standard approaches to the diagnosis |
|
|
197 | (53) |
|
8.1 Signs, symptoms, and laboratory tests |
|
|
197 | (20) |
|
|
|
|
|
|
|
|
|
|
|
8.2 Plain radiographic features of osteoarthritis |
|
|
217 | (20) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8.3 The natural history and prognosis of osteoarthritis |
|
|
237 | (13) |
|
|
|
|
|
|
|
|
|
|
|
9 Management of osteoarthritis |
|
|
250 | (153) |
|
9.1 Introduction: the comprehensive approach |
|
|
250 | (5) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9.2 Why does the patient with osteoarthritis hurt? |
|
|
255 | (6) |
|
|
|
|
|
|
9.3 Nonsteroidal anti-inflammatory drugs |
|
|
261 | (11) |
|
|
|
|
|
|
|
|
272 | (10) |
|
|
|
|
|
|
|
|
|
|
|
9.5 Economic considerations in the use of nonsteroidal anti-inflammatory drugs |
|
|
282 | (9) |
|
|
|
|
|
|
|
|
291 | (5) |
|
|
|
|
|
|
|
|
|
|
|
9.7 Topical capsaicin cream |
|
|
296 | (3) |
|
|
|
|
|
|
|
|
|
|
|
9.8 Intra-articular therapies in osteoarthritis |
|
|
299 | (8) |
|
|
|
|
|
|
|
|
|
|
|
|
|
307 | (8) |
|
|
|
|
|
|
|
|
|
|
|
9.10 The role of occupational therapy |
|
|
315 | (9) |
|
|
|
|
|
|
|
|
|
|
|
|
|
324 | (7) |
|
|
|
|
|
|
|
|
331 | (7) |
|
|
|
|
|
|
|
|
|
|
|
9.13 Depression in osteoarthritis |
|
|
338 | (11) |
|
|
|
|
|
|
|
|
|
|
|
9.14 Coping strategies for the patient with osteoarthritis |
|
|
349 | (10) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
359 | (19) |
|
|
|
|
|
|
9.16 Surgical approaches to preserving and restoring articular cartilage |
|
|
378 | (10) |
|
|
|
|
|
|
|
|
|
|
|
9.17 Arthroplasty and its complications |
|
|
388 | (15) |
|
|
|
|
|
|
10 Evaluating outcome in osteoarthritis for research and clinical practice |
|
|
403 | (12) |
|
|
|
|
|
|
|
|
|
|
|
11 Prospects for pharmacological modifications of joint breakdown in osteoarthritis |
|
|
415 | (116) |
|
|
|
415 | (2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11.2 Disease-modifying osteoarthritis drugs |
|
|
417 | (12) |
|
|
|
|
|
|
|
|
|
|
|
11.3 Advantages afforded by the use of animal models for evaluation of potential disease-modifying osteoarthritis drugs (DMOADs) |
|
|
429 | (10) |
|
|
|
|
|
|
11.4 The role of animal models in the discovery of novel disease-modifying osteoarthritis drugs (DMOADs) |
|
|
439 | (11) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11.5 Assessment of changes in joint tissues in patients treated with a disease-modifying osteoarthritis drug (DMOAD): monitoring outcomes |
|
|
450 | (81) |
|
11.5.1 Radiographic grading systems |
|
|
450 | (9) |
|
|
|
|
|
|
|
|
|
|
|
11.5.2 Quantitation of radiographic changes |
|
|
459 | (14) |
|
J. Christopher Buckland-Wright |
|
|
|
|
|
11.5.3 Magnetic resonance imaging |
|
|
473 | (21) |
|
|
|
|
|
|
11.5.4 Arthroscopic evaluation of knee articular cartilage |
|
|
494 | (12) |
|
|
|
|
|
|
|
|
|
|
|
|
|
506 | (6) |
|
|
|
|
|
|
|
|
512 | (7) |
|
|
|
|
|
|
11.5.7 Defining and validating the clinical role of molecular markers in osteoarthritis |
|
|
519 | (12) |
|
|
|
|
|
|
|
|
|
|
|
12 Design of clinical trials for evaluation of disease-modifying osteoarthritis drugs (DMOADs) and of new agents for symptomatic treatment of osteoarthritis |
|
|
531 | (12) |
|
|
|
|
|
| Appendix 1 The American College of Rheumatology (ACR) criteria for the classification and reporting of osteoarthritis |
|
543 | (2) |
| Appendix 2 Lequesne's Algofunctional Lower Limb Indices |
|
545 | (2) |
| Appendix 3 WOMAC Osteoarthritis Index Version LK3.0 |
|
547 | (4) |
| Appendix 4 Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society |
|
551 | (27) |
| Appendix 5 Protocols for radiography |
|
578 | (3) |
|
J. Christopher Buckland-Wright |
|
|
|
|
| Index |
|
581 | |
Shopping Cart
Need Help? eService@ecampus.com
Copyright© 1999-2010
